OmniActive presents poster on study featuring Lutemax 2020 at macular carotenoids conference

Published: 7-Jul-2015
Ingredients Dietary supplements Active Nutrition Food

Soluble lutein inhibits cholinesterase and reduces ultraviolet radiation-induced inflammation and immunosuppression: an in vitro model


OmniActive Health Technologies is presenting a poster on the study, Soluble Lutein Inhibits Cholinesterase and Reduces Ultraviolet Radiation-Induced Inflammation and Immunosuppression: In vitro Model, at The Macular Carotenoids Conference’s (MCC) annual meeting, taking place from 8-10 July at Downing College, Cambridge University (UK).

The study was conducted by Vijaya Juturu PhD, FACN, Manager of Global Scientific and Clinical Affairs, Khadija Ghanam, PhD, Clinical Nutritional Biochemist and Jayant Deshpande, PhD, CTO, all from OmniActive Health Technologies.

This in vitro study evaluated the effect of the macular carotenoids — lutein and the two zeaxanthin isomers (Lutemax 2020) — on cholinesterase activity and antioxidant enzymes in response to ultraviolet (UV) irradiation.

Lutein and zeaxanthin isomers may ameliorate the effects of mild UV irradiation on Retinal Pigment Epitheleal (RPE) cells, as shown by the expression of genes involved in cell proliferation, inflammation, immune function and wound healing.

Lutein and zeaxanthin isomers inhibited cholinesterase activity and enhanced catalase activity in cells exposed to mild irradiation. These results suggest inhibition of cholinesterase enzyme and enhancing antioxidant enzymes may have several therapeutic applications such as neurodegenerative disorders and myasthenia gravis.

'We are excited to see from this Lutemax 2020 study these new insights into the critical role that lutein and zeaxanthin isomers (RR-zeaxanthin and RS (meso)-zeaxanthin) may play in eye health, specifically as potent antioxidants and anti-inflammatory agents protecting retinal tissue,' stated Jayant Desphande, Chief Technology Officer, OmniActive Health Technologies.

OmniActive — leaders in scientifically validated, premium ingredients — offers the most comprehensive line of macular carotenoids. The study is a product of OmniActive’s robust scientific programme as well as another significant addition to the growing science on the macular carotenoids.

  • Companies:
  • OmniActive Health Technologies
See more

You may also like

Ingredients

OmniActive Health Technologies reveals results of new studies on its ashwagandha extract: Zenroot

Read more
OmniActive announced results from two newly published, peer-reviewed clinical studies demonstrating the bioavailability and efficacy of Zenroot

Trending Articles

  1. Arjuna Natural’s Shoden receives Non-GMO Project verification Arjuna Natural, a manufacturer and innovator of standardised botanical extracts since 1989, is thrilled to announce that it has received Non-GMO Project verification for Shoden, its clinically studied ashwagandha extract
  2. PhytoGaia to unveil next-gen palm bioactives for clean & sustainable beauty PhytoGaia to unveil next-gen palm bioactives for clean & sustainable beauty at NYSCC Suppliers’ Day and Sustainable Cosmetics Summit 2025
  3. CBG and CBG-A: exploring the therapeutic potential of cannabis’ “Mother Cannabinoids” Broughton highlights early research into the non-psychoactive cannabinoids CBG and CBG-A and offers expert guidance on developing safe, science-backed products for the growing cannabis health market
  4. American Heart Association issues new advisory on ultraprocessed foods and heart health The American Heart Association has released a new Science Advisory in "Circulation" highlighting the growing health risks associated with ultraprocessed foods (UPFs) and calling for research, policy and consumer action to reduce the intake of the most harmful products
  5. Large proportion of the US population are deficient in key nutrients, data suggests Many are deficient in omega-3, magnesium and vitamin D, and findings suggest that sufficient intake of these nutrients can reduce the risk of breast cancer

Upcoming event

Vitafoods Asia

17–19 September 2025 | Exhibition | Bangkok See all

You may also like

Ingredients

OmniActive Health Technologies reveals results of new studies on its ashwagandha extract: Zenroot

OmniActive announced results from two newly published, peer-reviewed clinical studies demonstrating the bioavailability and efficacy of Zenroot
Ingredients

OmniActive's lutein ingredient gets the FDA nod for infant formula use

Lutemax Free Lutein is now considered GRAS in the US, and is suitable for use in early life nutrition products
Ingredients

OmniActive launches sleep, stress and mood nutraceuticals, Sleeproot and Zenroot in EU

Following the success of both ingredients in the US, OmniActive has launched the valerian and ashwagandha-derived ingredients in select European countries
Ingredients

OmniActive's Muvz nutraceutical blend boosts joint health in new study

The proprietary synergistic blend of ginger and Chinese chastetree could improve musculoskeletal health and joint comfort in 30 days, as well as mobility in 90 days
Ingredients

Sleeproot shown to increase sleep duration on day 1, reports OmniActive study

OmniActive Health Technologies shares new data on Sleeproot, its proprietary low-dose valerian extract, revealing that it supports a statistically significant increase in sleep duration starting on the first day of use
Ingredients

OmniActive acquires functional ingredients specialist, ENovate Biolife

The purchase will bolster OmniActive's range of botanical nutraceuticals for active nutrition, joint health, heart health and men's wellness
Training & Education

OmniActive partners with CRN to raise awareness about carotenoids for prenatal nutrition

The partnership with the CRN endeavours to inform healthcare professionals about the benefits lutein and xeaxanthin for prenatal macular health in mum and baby
Subscribe now